Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria

1. A method for treating, reducing, or ameliorating all infection in a subject, the method comprising administering to said subject in need thereof a composition comprising: (a) a fluoroquinolone having Formula IV or a salt thereof present in an amount effective to treat, reduce, or ameliorate an infection caused by ofloxacin-resistant Enterobacteriaceae with MIC 90 range of 4-32 μg/ml in vitro, ofloxacin-resistant S. aureus with MIC 90 range of 0.5-8 μg/ml in vitro, levofloxacin-resistant S. pneumonia with MIC 90 range of 0.5-8 μg/ml in vitro, gentamicin-resistant S. aureus with MIC 90 range of 0.006-8 μg/ml in vitro, ampicillin-resistant H. influenza with MIC 90 less than or equal to 0.06 μg/ml in vitro, or vancomycin-resistant S. aureus with MIC 90 range of 1-4 μg/ml in vitro; or (b) a fluoroquinolone having Formula VI present in an amount effective to treat, reduce, or ameliorate an infection caused by gentamicin-resistant S. aureus with MIC 90 range of 0.006-4 μg/m in vitro or ampicillin-resistant H. influenza with MIC 90 less than or equal to 0.06 μg/ml in vitro;

2. The method of claim 1 , wherein the composition is administered topically, orally, or systemically.

3. The method of claim 1 , where the composition is administered topically.

4. The method of claim 1 , wherein the infection is an infection of an eye, ear, respiratory system, or a combination thereof.

5. A method for treating, reducing, or ameliorating an infection in a subject, the method comprising: (a) ascertaining that a specimen from a site of infection contains a bacterium that is resistant to an antibacterial drug that is selected from the group consisting of gentamycin, vancomycin, ofloxacin, ciprofloxacin, and levofloxacin; and (b) administering to said subject in need thereof a composition comprising (i) a fluoroquinolone having Formula IV or a salt thereof present in an amount effective to treat, reduce, or ameliorate an infection caused by ofloxacin-resistant Enterobacteriaceae with MIC 90 range of 4-32 μg/ml in vitro, ofloxacin-resistant S. aureus with MIC 90 range of 0.5-8 μg/ml in vitro, levofloxacin-resistant S. pneumonia with MIC 90 range of 0.5-8 μg/ml in vitro, gentamicin-resistant S. aureus with MIC 90 range of 0.006-8 μg/ml in vitro, ampicillin-resistant H. influenza with MIC 90 less than or equal to 0.06 μg/ml in vitro, or vancomycin-resistant S. aureus with MIC 90 range of 1-4 μg/ml in vitro; or (ii) a fluoroquinolone having Formula VI present in an amount effective to treat, reduce, or ameliorate an infection caused by, ofloxacin-resistant S. aureus with MIC 90 range of 0.5-8 μg/ml in vitro or ampicillin-resistant H. influenza with MIC 90 less than or equal to 0.06 μg/ml in vitro;